NCT04289649View on ClinicalTrials.gov

K-924 Phase III Confirmatory Study

PHASE3CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

November 21, 2020

Study Completion Date

November 21, 2020

Conditions
Hypercholesterolemia
Interventions
DRUG

K-924 LD

Pitavastatin 2 mg / Ezetimibe 10 mg tables

DRUG

K-924 HD

Pitavastatin 4 mg / Ezetimibe 10 mg tables

DRUG

K-924 LD Placebo

Pitavastain 2 mg

DRUG

K-924 HD Placebo

Pitavastain 4 mg

Trial Locations (3)

Unknown

Medical Corporation Heishinkai OCROM Clinic, Osaka

Medical Corporation Heishinkai OPHAC Hospital, Osaka

Medical Corporation Heishinkai ToCROM Clinic, Tokyo

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT04289649 - K-924 Phase III Confirmatory Study | Biotech Hunter | Biotech Hunter